Pluristem Therapeutics : Analyst and investor call May 3, 2021- presentation

Analyst and Investor Call - HCT Phase I Topline Results

May 3, 2021

Credit: Haim Magiore

Inspired by Life

Agenda

Yaky Yanay,

CEO and President

Hematological deficiencies PLX-R18 product candidate Company's pipeline

2

Nitsan Halevy, MD	Jacob Rowe, MD, FACP		Chen Franco-Yehuda,
Chief Medical Officer	Director Hematology,		CFO
		Shaare Zedek Medical Center,
		Jerusalem
Phase I HCT -	Clinical	Financial overview
topline results	perspective

Forward Looking Statements

3

This presentation contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, we are using forward-looking statements when we discuss that PLX cells may provide a safer and more effective therapeutic benefit than current technologies, that PLX-R18 may potentially enhance the production of three blood cell lineages, that PLX-R18 may potentially reduce transfusion dependency, the belief that PLX-R18 affects the regeneration activity of the hematopoietic cells, its intention to push forward with the clinical development of PLX-R18 with the goal of establishing it as the new standard of care in the field and the expected timing of the expected end of enrollment in our various studies. These forward- looking statements and their implications are based on the current expectations of our management only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause our actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting us, reference is made to our reports filed from time to time with the Securities and Exchange Commission.

Hematological Deficiencies

Phase I

Open-label,dose-escalation study to evaluate the safety of intramuscular injections of PLX-18 in subjects with incomplete hematopoietic recovery following Hematopoietic Cell Transplantation (HCT)

4

The Need: Poor Graft Functions

• In patients suffering from a life-threatening condition of incomplete hematopoietic recovery, graft function remain poor, in which they fail to develop satisfactory blood counts in some or all blood cell lineages
• Available current treatments target only one of the three blood cell lineages
• These patients are vulnerable to bleeding and recurrent infections, requiring repeated costly transfusions of blood products, which only provide a short-term solution

5